Celator® Pharmaceuticals Announces Data to be Presented at the American Society of Hematology Annual Meeting Read more: http://www.sacbee.com/2010/11

Celator Pharmaceuticals today announced that three abstracts on its lead program, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, will be presented at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, including a podium presentation on results from a randomized, Phase 2 trial in elderly patients with newly diagnosed that compared treatment with CPX-351 to conventional cytarabine and daunorubicin (the "7+3" regimen), the current standard of care.